Faculty profile

Shashi Gujar

ResearcherPathologyDalhousie University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Dalhousie University directory, so their courses may be missing. Find their university profile.

Shashi Gujar

Researcher

Pathology

Health Sciences

Dalhousie University

Halifax, Nova Scotia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
17 publications in the last five years, latest in 2026.
Senior (last) author on 7 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2020.
Supervised 1 trainee who won CIHR awards, most recently in 2016.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

171

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Antitumor Immunity Cancer Cancer Immunotherapy Mhc Class I Oncolytic Virus

Latest papers

TRPML1 loss disrupts lysosome-mitochondria homeostasis and sensitizes MDA-MB-231 triple-negative breast cancer cells to chemotherapy.
The Journal of biological chemistry · 2026
High frailty index scores predict mortality and changes in blood-based biomarkers in aging female mice.
The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions.
Journal for immunotherapy of cancer · 2026 · first author

All 62 publications

Latest funding

Investigating the role of LINC01929 in regulating processes critical for breast cancer progression
CIHR · 2023 · Co-investigator
$1,093,950
Identification of lncRNAs that regulate biological processes required for breast cancer progression
CIHR · 2022 · Co-investigator
$100,000
Precision Image-Guided Ultrasound Ablation of Brain Tumors: A Longitudinal Pre-Clinical Study using a Newly Developed Platform
CIHR · 2022 · Co-investigator
$596,700

All 12 grants and awards

62 publications.

TRPML1 loss disrupts lysosome-mitochondria homeostasis and sensitizes MDA-MB-231 triple-negative breast cancer cells to chemotherapy.

Syeda AK, Almasi S, Benson CJ, Kennedy BE, Yoast RM, Emrich SM, Delima-Baril A, Slade L, Pakkiriswami S, Vijayan VV, Sheela UB, Gujar S, Pulinilkunnil T, Trebak M, El Hiani Y

The Journal of biological chemistry2026

DOI: 10.1016/j.jbc.2026.113596 PMID: 42772563

High frailty index scores predict mortality and changes in blood-based biomarkers in aging female mice.

Bisset ES, Gujar S, Rockwood K, Howlett SE

The journals of gerontology. Series A, Biological sciences and medical sciences2026

DOI: 10.1093/gerona/glag158 PMID: 42275167

Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions.

Gujar S, Pol JG, Vijayan VV, Gopalakrishnan Nair P, Babukuttan Sheela U, Banerjee A, Kroemer G

Journal for immunotherapy of cancer2026First author

DOI: 10.1136/jitc-2026-015132 PMID: 42236116

Interplay between viral oncolysis and host immunity in Newcastle disease virus-based cancer therapy.

Mehta D, Gujar S, Kumar S

Seminars in immunology2026

DOI: 10.1016/j.smim.2026.102032 PMID: 42155154

Dendritic cells as central coordinators of oncolytic virus-induced antitumor immunity.

Ezzaldeen EM, Vijayan VV, Nair PG, Sheela UB, Banerjee A, Gujar S

Seminars in immunology2026Senior author

DOI: 10.1016/j.smim.2026.102033 PMID: 42150415

Targeting Age-Associated Immune Senescence via Nanoparticle-Based Metabolic Reprogramming.

Nair PG, Sheela UB, Vijayan VV, Howlett SE, Cullis P, Gujar S

ACS nano2026Senior author

DOI: 10.1021/acsnano.5c18638 PMID: 42102396

LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target.

Venkatesh J, Wasson MD, Arun RP, Cahill HF, Walker OL, Dean CA, Fernando W, MacLean MR, McLean ME, Khan B, Kruth PS, Sultonova M, Nersesian S, Lee SN, Longjohn MN, Hughes CS, Belbin TJ, Gaston D, Paulo JA, Knapp GC, Bethune G, Gujar S, Boudreau JE, Murphy JP, Marcato P

iScience2026

DOI: 10.1016/j.isci.2026.115381 PMID: 41993692

Subversion of kynurenine-induced AHR activation in CD8 T cells by kynureninase-expressing antigen-presenting cells.

Giacomantonio MA, Vijayan VV, Nair PG, Pathak GP, Kennedy BE, Paulo JA, McMillen T, Banerjee A, Kumar V, Sultonova M, Sommer T, Owens N, Sheela UB, Atif J, MacParland SA, Gygi SP, Murphy JP, Gujar S

Cell reports2026Senior author

DOI: 10.1016/j.celrep.2026.117149 PMID: 41863799

THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer.

Walker OL, Wasson MD, Kumar V, Nersesian S, Venkatesh J, Vijayan VV, Coates L, Fernando W, Arun RP, Cahill HF, Baker E, Dahn ML, Slauenwhite D, Cruickshank BM, Barnes P, Longjohn MN, Belbin TJ, Gaston D, Knapp GC, Melvin J, Gujar S, Boudreau JE, Bethune G, Marcato P

Biomarker research2025

DOI: 10.1186/s40364-025-00850-7 PMID: 41153058

Targeting TRPML3 inhibits proliferation and invasion, and enhances doxorubicin sensitivity by disrupting lysosomal acidification and mitochondrial function in triple-negative breast cancer.

Gomes GMA, Xu M, Syeda AKR, Raudonis R, Almasi S, Vijayan VV, Gujar S, Dong X, Cheng Z, Pulinilkunnil T, El Hiani Y

Biochimica et biophysica acta. Molecular cell research2025

DOI: 10.1016/j.bbamcr.2025.119979 PMID: 40348344

Something wrong or missing on this profile? Suggest a correction

Shashi Gujar

Research

Latest papers

Latest funding

TRPML1 loss disrupts lysosome-mitochondria homeostasis and sensitizes MDA-MB-231 triple-negative breast cancer cells to chemotherapy.

High frailty index scores predict mortality and changes in blood-based biomarkers in aging female mice.

Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions.

Interplay between viral oncolysis and host immunity in Newcastle disease virus-based cancer therapy.

Dendritic cells as central coordinators of oncolytic virus-induced antitumor immunity.

Targeting Age-Associated Immune Senescence via Nanoparticle-Based Metabolic Reprogramming.

LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target.

Subversion of kynurenine-induced AHR activation in CD8 T cells by kynureninase-expressing antigen-presenting cells.

THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer.

Targeting TRPML3 inhibits proliferation and invasion, and enhances doxorubicin sensitivity by disrupting lysosomal acidification and mitochondrial function in triple-negative breast cancer.

Frequent collaborators

Paola Marcato

Thomas Pulinilkunnil

Sheila Singh

Patrick Lee

Yasir Mohamud

Ina Dobrinski

John Bell

Jean-Simon Diallo

Michael Sacher

Martin Post

Pieter Cullis

Sabah Hussain

Caigan Du

Honglin Luo

Sandra Turcotte

Maya Shmulevitz

Kenneth Rockwood

Gary Sweeney

Isabella Caniggia

Roy Duncan

Nigil Haroon

Lothar Lilge

Steve Jean